John Anderson - Stille AB Head Devel
| STIL Stock | SEK 220.00 9.00 4.27% |
Insider
John Anderson is Head Devel of Stille AB
| Age | 48 |
| Phone | 46 8 58 85 80 00 |
| Web | https://www.stille.se |
John Anderson Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Anderson against Stille AB stock is an integral part of due diligence when investing in Stille AB. John Anderson insider activity provides valuable insight into whether Stille AB is net buyers or sellers over its current business cycle. Note, Stille AB insiders must abide by specific rules, including filing SEC forms every time they buy or sell Stille AB'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Anderson over three months ago Disposition of 10444 shares by John Anderson of Knowles Cor at 18.5 subject to Rule 16b-3 | ||
John Anderson over three months ago Disposition of 46382 shares by John Anderson of Knowles Cor at 14.29 subject to Rule 16b-3 |
Stille AB Management Efficiency
The company has return on total asset (ROA) of 0.0588 % which means that it generated a profit of $0.0588 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1601 %, meaning that it generated $0.1601 on every $100 dollars invested by stockholders. Stille AB's management efficiency ratios could be used to measure how well Stille AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Linda Andersson | Genovis AB | 47 | |
| Christina Hugosson | Boule Diagnostics AB | 60 | |
| Simon Ostergaard | CellaVision AB | 52 | |
| Susanne Ahlberg | Genovis AB | 66 | |
| Nina Wallander | CellaVision AB | 49 | |
| Urban Strindlov | CellaVision AB | 59 | |
| Aishat Bislieva | Boule Diagnostics AB | N/A | |
| Lars Levin | C Rad AB | 52 | |
| Yve Thorenburg | CellaVision AB | 65 | |
| Jesper Soderqvist | Boule Diagnostics AB | 57 | |
| Priscilla Kazumba | C Rad AB | N/A | |
| Magnus Langberg | Genovis AB | 52 | |
| Mikael Ekholm | Boule Diagnostics AB | 61 | |
| Emelie Gozzi | C Rad AB | N/A | |
| Karen Bornstein | Boule Diagnostics AB | N/A | |
| Michael Eliott | Boule Diagnostics AB | N/A | |
| Helena Borjesson | Boule Diagnostics AB | N/A | |
| Hakan Axelsson | C Rad AB | 55 | |
| Julien Veyssy | CellaVision AB | 40 | |
| Rikke Rytter | Genovis AB | 56 | |
| Annette Colin | Boule Diagnostics AB | N/A | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0588 |
Stille AB Management Team
Elected by the shareholders, the Stille AB's board of directors comprises two types of representatives: Stille AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stille. The board's role is to monitor Stille AB's management team and ensure that shareholders' interests are well served. Stille AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stille AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Niklas Carln, CFO Board | ||
| John Anderson, Head Devel | ||
| Hanna Wilkman, MD CEO |
Stille Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stille AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0588 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 667.84 M | |||
| Shares Outstanding | 5.01 M | |||
| Shares Owned By Insiders | 46.70 % | |||
| Shares Owned By Institutions | 39.07 % | |||
| Price To Earning | 19.85 X | |||
| Price To Book | 3.37 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Stille Stock Analysis
When running Stille AB's price analysis, check to measure Stille AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stille AB is operating at the current time. Most of Stille AB's value examination focuses on studying past and present price action to predict the probability of Stille AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stille AB's price. Additionally, you may evaluate how the addition of Stille AB to your portfolios can decrease your overall portfolio volatility.